缓解时克隆性造血增殖的持续存在可能是患者患继发性血液肿瘤的一个诱发因素,因为多达10%的 NPM1 突变AML复发患者可能会失去 NPM1 突变克隆。NPM1 突变在AML中经常与其他突变共存,这种组合可能会影响疾病行为和风险分类(图 1)。 分子MRD...
NPM1突变的急性髓系白血病(AML)患者在接受强化化疗后预后良好,但大多数微小残留病灶(MRD)持续存在或复发的患者最终会出现疾病进展或复发。由于NPM1的RT-qPCR检测到的分子学复发先于血液学复发2~4个月,因此许多中心在检测到MRD后即进行异...
NPM1 mutation (NMP1c) is a frequently mutated gene found in AML, and NMP1 mutated AML depends on menin-MLL interaction for leukemogenesis. Given the fact that wild type MLL and MLLr have similar leukemogenesis-driven target genes like HOXA and MEIS1, as well as the same binding pocket ...
我是一名54岁的女性,24年前被诊断出患有AML伴NPM1突变。经过第一次化疗后,我的病情得到了控制,出院回家休养。然而,在最近的血常规检查中,我发现C反应蛋白升高,纤维蛋白原和D二聚体异常。这让我非常担心,是否意味着我的病情复发了? 我决定寻求专业医生的帮助,于是通过互联网医院联系了一位经验丰富的医生。我们进...
Single-agent mezigdomide was efficacious in 5 patient-derived xenograft models of KMT2A-r and 1 NPM1c AML. The combination of mezigdomide with the menin inhibitor VTP-50469 increased survival and prevented and overcame MEN1 mutations that mediate resistance in patients receiving menin inhibitor...
NPM1-mutated AML: targeting by disassembling Inhis issueflood,alusundollegues provide preclinical evidenceshatargeting nucleophosmin (NPM1) induces differentiationnd deathfcuteyeloid leukemia (AML)ell... B Falini,MP Martelli - 《Blood》 被引量: 18发表: 2011年...
Nucleophosmin (NPM1) mutations represent an attractive therapeutic target in acute myeloid leukemia (AML) because they are common (∼30% AML), stable, and behave as a founder genetic lesion. Oncoprotein targeting can be a successful strategy to treat AML, as proved in acute promyelocytic leukemi...
Nucleophosmin (NPM1) is frequently mutated in acute myeloid leukemia (AML) and displays Cy localization in mutated nucleophosmin (NPMc+) AML. Here we show that NPM1 directly interacts with herpes virus-associated ubiquitin specific protease (HAUSP), which is known as a PTEN deubiquitinating enzyme...
2024年1月26-28日,“中国临床肿瘤学会(CSCO)白血病专家委员会、淋巴瘤专家委员会及骨髓瘤筹备委员会工作会议暨2024年CSCO血液及淋巴瘤、骨髓瘤疾病学术大会”在海口成功举办。会议期间,医脉通特邀苏州大学附属第一医院陈苏宁教授接受采访,...
尽管NPM1突变急性髓系白血病(AML)预后普遍良好,但许多患者仍会复发并死亡。据报道,许多分子生物学和临床特征与不良预后相关,包括年龄、白细胞计数(WCC)、继发性疾病、非ABD NPM1突变类型、NPM1突变负担和共突变。此外,现已经确定诱导化疗...